Related Experiment Videos
[Pain therapy in HIV-associated polyneuropathy]
I W Husstedt1, S Böckenholt, B Kammer-Suhr
1Kopfschmerz- und Neurologische HIV-Ambulanz, Klinik und Poliklinik für Neurologie, Westfälische Wilhelms-Universität Münster. husstedt@uni-muenster.de
Schmerz (Berlin, Germany)
|January 26, 2002
Summary
Pain is a significant issue for patients with HIV infection, affecting up to 50% and requiring specialized management. Early diagnosis and monitoring of HIV-associated polyneuropathy are crucial for effective pain therapy.
Area of Science:
- Neurology
- Infectious Diseases
- Pain Management
Background:
- Pain significantly impacts individuals with HIV infection, with up to 50% experiencing severe pain in later stages.
- Neurological manifestations, including polyneuropathy and myopathy, are common complications of HIV.
Observation:
- HIV-associated distal-symmetric polyneuropathy is the most prevalent form, characterized by pain, sensory disturbances, and motor deficits.
- Neurological examination and neurophysiological studies are essential for monitoring polyneuropathy progression.
- Myopathy symptoms include muscle pain and elevated creatine kinase (CK), often requiring biopsy for diagnosis.
Findings:
- Antiretroviral therapy is not indicated for HIV-associated distal-symmetric polyneuropathy itself.
- Symptomatic treatment involves antiepileptics (e.g., gabapentin), antidepressants (e.g., amitriptyline), and opiates.
- Psychotherapeutic and thymoleptic therapies are vital for managing associated depressive disorders.
Implications:
- Careful consideration of neurotoxic medications is necessary to prevent or manage drug-induced polyneuropathy.
- Treatment of HIV-associated polymyositis may involve NSAIDs, corticosteroids, immunoglobulins, or plasmapheresis.
- Individualized therapeutic strategies are crucial for managing complex neurological complications in HIV patients.